Inclusion Criteria:  Kidney transplant patients from Hospital de Clínicas de Porto Alegre (HCPA) between October 2018 to March 2020 who received a single 3 mg/kg ATG dose at the immediate postoperative period. Recipients of standard and low immunological risk (PRA - panel reactive antibodies <50% and without donor-specific antibodies), regardless of the time of cold ischemia and the presence of kidney failure in the donor. Control group consisting of patients from the same and previous period, who received fractionated ATG dosing up to 6 mg/kg total dose.  Exclusion Criteria:  Patients who used other induction strategies that did not include ATG in a single dose of 3 mg/kg or the fractionated dose of 6 mg/kg. Patients who died within 24 hours after transplantation. Patients who had a transplant nephrectomy within 24 hours after transplantation. Pediatric recipients (< 14 years old). Recipients with incomplete data.